Live
Natco Pharma’s, Mekaguda facility near Hyderabad, has received zero observations from the US health regulator.
The company in its filing stated, “….announce successful completion of regulatory inspection from the United States Food and Drug Administration (USFDA) for its active pharmaceutical ingredient (API) facility in Mekaguda Village, Hyderabad.”
The inspection was conducted by the USFDA during the period between February 12-16,2018, and the regulatory audit resulted in zero observations (no form 483 issued).
